Press Releases LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
2.39 ^USD	-9.47%		-9.81%	+51.27%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LAVA Therapeutics N : Form 6-K	May. 21	PU
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results	May. 21	GL
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference	May. 06	GL
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference	May. 06	AQ
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	Mar. 20	GL
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results	Mar. 20	AQ
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)	Mar. 05	GL
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	Jan. 30	AQ
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®	Jan. 25	GL
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	Nov. 16	GL
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	GL
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results	23-08-22	GL
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results	23-08-22	AQ
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference	23-08-14	GL
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway	23-06-14	GL
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway	23-06-14	AQ
LAVA Therapeutics N : Consolidated Financial Statements - Form 6-K	23-06-08	PU
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results	23-06-08	GL
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results	23-06-08	AQ
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development	23-06-01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Press Releases

Filters